A

Apnimed

Company Research Report: Apnimed



Company Overview



Name


Apnimed

Mission


Apnimed is built upon a simple idea – patients with Obstructive Sleep Apnea (OSA) need a simple, safe, and effective treatment that addresses the underlying biology of the disease.

Founded


No information is available

Key People


  • Larry Miller, MD - Chief Executive Officer

  • Ron Farkas, MD, PhD - Chief Medical Officer

  • Graham Goodrich - Chief Commercial Officer

  • Ted Harding - Chief Human Resources Officer

  • Dennis Molnar - President and Chief Operating Officer

  • Luigi Taranto Montemurro, MD - Chief Scientific Officer

  • David P. White, MD - Distinguished Medical Advisor

  • Gina Marek - Interim Chief Financial Officer


Headquarters


Cambridge, MA, USA

Number of Employees


No information is available

Revenue


No information is available

Notable Achievements


Apnimed is recognized for developing novel oral therapies for sleep apnea and has been named one of the best places to work by the Boston Business Journal in 2024. Additionally, it has been named a "Fierce 15" Biotech Company by Fierce Biotech in 2023.

Products



AD109


  • Description: AD109 is Apnimed’s lead product candidate designed to treat the underlying neuromuscular defect of OSA, improving upper airway muscle activity during sleep. It combines a novel NCE selective antimuscarinic (aroxybutynin) with a selective norepinephrine reuptake inhibitor (atomoxetine).

  • Key Features:

  • Targets two neurochemical pathways to control upper airway muscles during sleep.

  • Once-daily oral dosage.

  • Demonstrated significant improvements in clinical trials (AHI reduction, oxygenation, fatigue).

  • Fast Track designation by the FDA.


Recent Developments



New Products Launched


No information is available

Recent Developments & Partnerships


1. Clinical Trials & Studies:
  • LunAIRo Study: A Phase 3 randomized, double-blind, placebo-controlled, 1-year parallel-arm study of AD109.

  • SynAIRgy Study: A Phase 3 randomized, double-blind, placebo-controlled, 6-month parallel-arm study of AD109.


2. Exceptional Recognitions:
  • Named "Best Places to Work" by Boston Business Journal in 2024.

  • Recognized as one of the "Fierce 15" Biotech companies by Fierce Biotech in 2023.


3. Partnerships:
  • Joint Venture with Shionogi: Launched for the development of novel pharmacologic therapies for OSA and other sleep disorders, valued at $150 million.


4. Leadership Appointments:
  • Graham Goodrich: Joined as Chief Commercial Officer.

  • Ted Harding: Joined as Chief Human Resources Officer.


5. Clinical Developments:
  • Completion of enrollment in Phase 3 LunAIRo Study of AD109.

  • Initiation of patient dosing in the Phase 3 SynAIRgy clinical study of AD109.


Pipeline Products


JV Programs


  • Focus on other sleep and breathing diseases in collaboration with Shionogi-Apnimed Sleep Science.


Key Supporting Research


  • Extensive safety and efficacy data from 15+ Phase 1 and 2 clinical trials.

  • Positive results from Phase 2 MARIPOSA trial indicating significant clinical improvements.


Summary


Apnimed is at the forefront of developing transformative, oral pharmacologic therapies for obstructive sleep apnea, targeting the underlying neurobiological mechanisms. The company's lead product, AD109, is advancing through late-stage clinical trials, showing promise as a potential first-in-class treatment option.